4.7 Article

AQP4 antibody-positive Thai cases Clinical features and diagnostic problems

Journal

NEUROLOGY
Volume 77, Issue 9, Pages 827-834

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31822c61b1

Keywords

-

Funding

  1. Siriraj Hospital [R015232060]
  2. KAKENHI of The Ministry of Education, Culture, Sports, Science and Technology of Japan [19209032, 20390241, 21790828, 22229008]
  3. Ministry of Health, Labour and Welfare of Japan
  4. Merck Serono
  5. Bayer Schering Pharma
  6. Eisai Inc.
  7. sanofi-aventis
  8. Biogen Idec
  9. Mitsubishi Tanabe Pharma Corporation
  10. Ministry of Education, Science and Technology
  11. Astellas Pharma Inc.
  12. Takeda Pharmaceutical Company Limited
  13. Asahi Kasei Kuraray Medical Co., Ltd.
  14. Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN)
  15. Teva Pharmaceutical
  16. Teijin Pharma
  17. Kowa Pharmaceuticals America, Inc.
  18. Pfizer Inc
  19. Novartis
  20. Bayer Schering
  21. Grants-in-Aid for Scientific Research [19209032, 21790828, 20390241] Funding Source: KAKEN

Ask authors/readers for more resources

Objective: To evaluate the prevalence of aquaporin-4 (AQP4) antibody in Thai patients with idiopathic inflammatory demyelinating CNS diseases (IIDCDs) and to analyze the significance of the autoantibody to distinguish neuromyelitis optica (NMO) and other NMO spectrum disorders (ONMOSDs) from other IIDCDs, especially multiple sclerosis (MS). Methods: We retrospectively evaluated 135 consecutive patients with IIDCDs seen at the MS clinic at Siriraj Hospital, Bangkok, Thailand, and classified them into NMO, ONMOSDs, optic-spinal MS (OSMS), classic MS (CMS), and clinically isolated syndrome (CIS) groups in this order with accepted diagnostic criteria. The patients' coded sera were tested separately for AQP4 antibody. Then the relations between the clinical diagnosis and the AQP4 antibody serologic status were analyzed. Results: Among the 135 patients, 53 (39.3%) were AQP4 antibody-positive. Although the AQP4 antibody-positive group had features of NMO, such as female predominance, long cord lesions (>3 vertebral bodies), and CSF pleocytosis, only 18 patients (33% of 54) fully met Wingerchuk 2006 criteria except for AQP4 antibody-seropositive status. We also detected some AQP4 antibody-positive patients in the OSMS (4 of 7), CMS (11 of 46), and CIS (1 of 16) groups. These patients had been misdiagnosed with MS because they often had brain lesions and never underwent spinal cord MRI examination or lacked long cord lesions. Conclusions: AQP4 antibody was highly prevalent (almost 40%) in Thai patients with IIDCDs. Moreover, only one-third of AQP4 antibody-positive patients fully met Wingerchuk 2006 criteria, and many were misdiagnosed with MS. A sensitive AQP4 antibody assay is required in this region because the therapy for NMO is different from that for MS. Neurology (R) 2011;77:827-834

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available